Approach to the Patient with Possible Cardiovascular Disease¶
Chapter 243 | Part 6: Disorders of the Cardiovascular System
KEY CLINICAL POINTS¶
- Cardiovascular diseases are the leading cause of mortality globally, responsible for ~19 million deaths/year and 700,000 deaths/year in the U.S.
- Symptoms like chest discomfort, dyspnea, edema, and syncope are cardinal but nonspecific; differential diagnosis includes pulmonary, metabolic, and psychiatric conditions.
- NYHA functional classification is critical for assessing functional impairment and guiding management (Table 243-1).
- Electrocardiography, echocardiography, and imaging are essential for diagnosing structural and functional abnormalities.
- Risk factors for CAD include obesity, type 2 diabetes, metabolic syndrome, and gender-specific differences in pathogenesis.
1. DEFINITION & OVERVIEW¶
Cardiovascular disease (CVD) encompasses disorders of the heart and blood vessels, including coronary artery disease (CAD), arrhythmias, and heart failure. Symptoms arise from myocardial ischemia, impaired contractility, valvular obstruction, or arrhythmias. Key manifestations include chest discomfort (most commonly ischemia), dyspnea (pulmonary congestion or heart failure), edema (right-sided heart failure), and syncope (arrhythmias or structural abnormalities).
Table 243-1 New York Heart Association Functional Classification¶
| Class | Physical Activity Limitation | Symptoms During Activity |
|---|---|---|
| Class I | No limitation of physical activity | No symptoms with ordinary exertion |
| Class II | Slight limitation of physical activity | Ordinary activity causes symptoms |
| Class III | Marked limitation of physical activity | Less than ordinary activity causes symptoms; asymptomatic at rest |
| Class IV | Inability to carry out any physical activity without discomfort | Symptoms at rest |
1.1 Cardiac Symptoms and Mechanisms¶
Ischemia (oxygen supply-demand imbalance) causes chest discomfort (Chap. 15). Reduced cardiac output leads to fatigue and fluid retention (peripheral edema/ pulmonary congestion). Valvular obstruction mimics myocardial failure, while arrhythmias cause palpitations, hypotension, or syncope (Chap. 23).
2. EPIDEMIOLOGY¶
CVD is the leading cause of death globally (19 million/year) and in the U.S. (700,000/year). Mortality rates for coronary heart disease declined by 2/3 in the U.S. over 40 years but remain the top cause of death. Prevalence is rising in women due to obesity, diabetes, and metabolic syndrome. Cardiovascular diseases affect ~50% of adults in developed nations.
2.1 Risk Factors¶
Obesity, type 2 diabetes, metabolic syndrome, and inflammation are major risk factors. Women show greater pathogenic involvement of microvascular dysfunction and coronary microcirculation abnormalities compared to men.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Atherosclerosis, valvular dysfunction, and arrhythmias are central mechanisms. Women exhibit more coronary microvascular dysfunction and lower diagnostic accuracy in stress testing. Genetic factors (e.g., hypertrophic cardiomyopathy, Marfan syndrome) and polygenic risks (hypertension, diabetes) contribute to disease progression.
3.1 Gender Differences¶
Women have higher prevalence of microvascular dysfunction, coronary microcirculation abnormalities, and sudden cardiac death risks. Inflammatory and metabolic factors play more prominent roles in female CAD pathogenesis.
4. CLINICAL FEATURES¶
Symptoms vary by etiology: ischemia (chest discomfort), heart failure (dyspnea, edema), valvular disease (syncope, murmurs), and arrhythmias (palpitations). Exertional symptoms (e.g., dyspnea with stair climbing) are more indicative of cardiac disease than resting symptoms. Asymptomatic cases may present with murmurs, hypertension, or abnormal ECG findings.
4.1 Symptom-Exertion Relationship¶
Exertional dyspnea/chest discomfort is characteristic of cardiac disease. Resting symptoms may suggest noncardiac causes (e.g., anxiety, pulmonary disease). Functional impairment assessment must consider baseline activity levels and therapeutic regimens.
5. DIFFERENTIAL DIAGNOSIS¶
Cardiac symptoms overlap with noncardiac conditions: pulmonary disease (dyspnea), obesity (edema), anxiety (chest discomfort), and neurologic disorders (syncope). Noncardiac causes of chest pain include gastrointestinal issues, musculoskeletal pain, and panic attacks.
5.1 Common Mimickers¶
Pulmonary disorders (e.g., COPD), metabolic conditions (e.g., hyperthyroidism), psychiatric disorders (e.g., panic attacks), and musculoskeletal pain must be considered in differential diagnosis.
6. INVESTIGATIONS & DIAGNOSIS¶
Comprehensive evaluation includes clinical assessment, ECG, imaging (chest x-ray, echocardiography), and biomarkers (BNP, troponin). NYHA classification guides functional assessment. Diagnostic algorithms incorporate stress testing, imaging, and genetic testing for monogenic disorders.
6.1 Diagnostic Tools¶
ECG identifies arrhythmias, ischemia, or structural abnormalities. Echocardiography evaluates valvular function and cardiac anatomy. Stress testing assesses ischemia and functional capacity. Genetic testing is indicated for familial disorders (e.g., hypertrophic cardiomyopathy).
7. MANAGEMENT & TREATMENT¶
Management depends on severity and etiology: risk factor modification, pharmacologic therapy (antiplatelets, beta-blockers, ACE inhibitors), and surgical interventions (coronary revascularization, valve repair). Asymptomatic patients require risk stratification using lipid profiles, C-reactive protein, and imaging.
7.1 Risk Stratification¶
Asymptomatic individuals undergo combined clinical assessment, lipid profiling, and biomarker analysis. Early detection of CAD in high-risk patients (e.g., metabolic syndrome) prevents acute events.
8. PROGNOSIS & COMPLICATIONS¶
CVD remains the leading cause of mortality despite declining rates. Sudden cardiac death accounts for ~1/3 of deaths. Untreated heart failure leads to progressive fluid retention, pulmonary congestion, and systemic complications. Prognosis is influenced by disease severity, comorbidities, and response to therapy.
8.1 Complications¶
Progressive heart failure, arrhythmias, and thromboembolism are major complications. Untreated CAD may lead to acute myocardial infarction, stroke, or sudden death.
9. SPECIAL CONSIDERATIONS¶
Women have unique risk factors (microvascular dysfunction, hormonal influences) and may present with atypical symptoms. Pediatric and elderly populations require tailored assessments. Pregnancy-related cardiovascular risks (e.g., gestational hypertension) and age-related comorbidities (e.g., frailty) must be addressed.
9.1 Gender-Specific Considerations¶
Women exhibit higher prevalence of microvascular dysfunction and coronary microcirculation abnormalities. Inflammatory and metabolic factors play a greater role in female CAD pathogenesis compared to men.
10. KEY POINTS & CLINICAL PEARLS¶
- Cardiac symptoms are nonspecific; differential diagnosis is critical. 2. NYHA classification guides functional assessment and treatment planning. 3. Exertional symptoms are more indicative of cardiac disease than resting symptoms. 4. Women have unique pathogenic mechanisms and risk factors. 5. Early detection and risk stratification prevent acute cardiovascular events.